Innovent's mazdutide approved in China for weight management

Innovent Biologics (HKEX:1801) announced that its new drug application (NDA) for mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been approved by the NMPA for chronic weight management in Chinese adults with overweight or obesity. The approval is supported by data from the GLORY-1 Phase 3 clinical study, which demonstrated significant weight loss efficacy and metabolic benefits. At week 48, participants in the mazdutide 4mg and 6mg groups showed mean body weight reductions of 12.0% and 14.8% respectively, compared to a 0.5% reduction in the placebo group. Mazdutide is also undergoing NMPA review for glycemia control in adults with type 2 diabetes. The World Obesity Federation (WOF) estimates that obesity costs China around USD283.3 billion in GDP loss in 2020.